Physician profile
Robert W Cameron
NPI 1366422644
$3,496.48
in general payments reported to CMS, 2019-2025
27 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $285 · 2021: $426 · 2022: $451 · 2023: $577 · 2024: $610 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $766.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $492.07 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $474.29 | 2019-2022 | |
| Amgen INC. | $411.32 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $254.22 | 2021-2024 | Verquvo |
| Pfizer INC. | $158.46 | 2019-2025 | |
| Irhythm Technologies, INC. | $156.86 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $148.02 | 2019-2024 | Camzyos, Eliquis |
| Abbott Laboratories | $107.45 | 2022-2024 | Cardiomems, Amplatzer Talisman |
| Boston Scientific Corporation | $70.03 | 2024-2025 | Bodyguardian, Watchman Access System, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $61.88 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.80 | 2021-2025 | Lifevest |
| Lundbeck LLC | $41.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.30 | 2021-2022 | |
| Baxter Healthcare | $31.18 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $29.98 | 2021-2025 | Nexletol |
| Philips North America LLC | $25.33 | 2025 | Lm Undivided |
| Bayer Healthcare Pharmaceuticals INC. | $21.56 | 2025 | |
| Novo Nordisk INC | $20.13 | 2025 | Wegovy |
| Amryt Pharma Holdings LTD | $19.36 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.01 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $17.49 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $17.07 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $16.68 | 2023 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $15.35 | 2024 | Inspire |
| Bardy Diagnostics, INC. | $13.38 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $12.91 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.